We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
HYQVIA - (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
HYQVIA -
Date registered
Evaluation commenced
Decision date
Approval time
248 (255 working days)
Active ingredients
normal immunoglobulin
Registration type
EOI
Indication
Immunomodulatory therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy after stabilisation with intravenous immunoglobulin (IVIG).